Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-Cell Lymphoma of MALT-Type Pretreated With More Than One Prior Systemic Therapy Regimen (X05142).

Trial Profile

Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-Cell Lymphoma of MALT-Type Pretreated With More Than One Prior Systemic Therapy Regimen (X05142).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2012

At a glance

  • Drugs Bortezomib (Primary)
  • Indications MALT lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Feb 2012 Planned number of patients changed from 25 to 28 as reported by European Clinical Trials Database.
    • 28 Jul 2009 Actual end date (Nov 2007) and actual number of patients (12) added as reported by ClinicalTrials.gov.
    • 28 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top